Simavita Limited

SIM(TM) Sales, Strategy and Research Update - Seite 2

During the quarter, two leading operators in care services to the home have requested a pilot program within their at-home client base (which comprises approximately 6,000 individual aged homecare customers).

The application of SIM™ by the Queensland Department of Health in geriatric units at two major hospitals will commence from January 2016. This contract represents the equivalent of approximately 18 new additional aged care sites in terms of contracted value.

The Company is also continuing its sales and marketing activities in the residential aged care market, and the pipeline from groups interested in new pilot programs or further engagement currently represents over 11,500 beds.

Customer research continues to demonstrate a range of SIM™ clinical benefits

Simavita's customers are continuing to report significant clinical benefits from the deployment of the SIM™ technology.

Recently, Castlemaine Health, a regional aged care provider, in Victoria conducted a SIM™ pilot across 16 residents at one of their sites. This resulted in an outstanding reduction in falls, urinary tract infections and skin breakdowns and the group is now in discussions to deploy SIM™ across their 4 sites.

During the quarter, the Company also conducted a study (116 assessments, across 6 sites in New South Wales, Queensland and Western Australia) which demonstrated a 19% cost reduction in the cost of consumables as a result of implementing the SIM™ Plan.

CEO commentary

CEO of Simavita, Philippa Lewis commented, "We're very pleased to be able to report this combination of a number of new customer agreements, range of new pilot programs and a very strong pipeline. The research results are proving the value proposition and clinical outcomes that SIM™ can deliver. There is no doubt that leading care providers who are dedicated to best practice are seeing the benefits of SIM™ and are committing to its implementation. SIM™ data and the care plans it delivers is a unique and powerful way to drive improved major clinical outcomes and deliver cost and efficiencies around the world."